[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-349690-105":59,"doc-detail-349690-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","can-we-interpret-analyses-of-etiologic-heterogeneity-when-molecular-markers-are-used-to-classify-tumors","Can We Interpret Analyses of Etiologic Heterogeneity When Molecular Markers Are Used to Classify Tumors?","","Analyses of etiologic heterogeneity use molecular markers to subtype cancers and to assess whether an exposure is more strongly linked to one tumor subtype than others, even when those markers may function as mediators of exposure–disease relationships. A study constructs seven causal model scenarios using postmenopausal breast cancer literature, varying whether molecular markers mediate or do not mediate effects while subtyping disease. Results show similar heterogeneity findings across mediation models, and certain non-effect marker scenarios still yield evidence of heterogeneity. The method cannot distinguish modeled causal scenarios when mediating versus nonmediating marker roles are used, with implications for interpreting obesity-related pathways and receptor status subtypes.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/can-we-interpret-analyses-of-etiologic-heterogeneity-when-molecular-markers-are-used-to-classify-tumors/349690/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/can-we-interpret-analyses-of-etiologic-heterogeneity-when-molecular-markers-are-used-to-classify-tumors/349690.png","ImageObject",300,407,{"name":92,"@type":93},"Himbo","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the etiologic heterogeneity design and how are molecular markers used in it?","Question",{"text":112,"@type":113},"Etiologic heterogeneity analyses use tumor characteristics and molecular markers to split a cancer defined by a site into subgroups. These subgroups are intended to be more homogeneous with respect to a suspected causal factor.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does the study evaluate whether etiologic heterogeneity analyses can be interpreted under mediation?",{"text":117,"@type":113},"The study creates seven causal model scenarios from literature on postmenopausal breast cancer. It varies relationships among an exposure, a molecular marker (mediating or nonmediating), and disease, using numerical examples to assess how well analyses identify distinct etiologic pathways.",{"name":119,"@type":110,"acceptedAnswer":120},"What do the results and conclusions indicate about distinguishing causal scenarios using molecular-marker subtyping?",{"text":121,"@type":113},"Heterogeneity analyses give similar results across multiple causal mediation models even when the mediating role of the molecular marker changes. The method cannot distinguish between the modeled causal scenarios when a mediating or nonmediating molecular marker is used to subtype tumors.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},349690,1790449447,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":29,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},687197100911,"https://ap-avatar.wpscdn.com/avatar/a000239b6f1da00475?x-image-process=image/resize,m_fixed,w_180,h_180&k=1785132997149421697","Can We Interpret Analyses of Etiologic Heterogeneity When Molecular Markers Are Used to Classify Tumors?  \nStephen J. Mooney1 and Andrew G. Rundle2  \n|  |  | A |  | B | S |  | T | R |  | A |  | C | T |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n|  | Background: Analyses of etiologic heterogeneity use molecular markers to subtype cancers (e.g., breast cancer) and test whether an exposure is more strongly associated with one tumor subtype as opposed to other subtypes. However, these molecular markers (e.g., a mutated oncogene) may best be conceptualized as mediators of exposure–disease relationships.\u003Cbr>Methods: Seven model causal scenarios, based on data from the literature on postmenopausal breast cancer, were created with varying relationships between an exposure, a mediating or nonmediating molecular marker, and a disease status, with molecular marker used to subtype the disease. Using numerical examples, we assessed how well the analyses of etiologic heterogeneity identify the distinct etiologic pathways in these seven scenarios.\u003Cbr>Results: Etiologic heterogeneity analyses of the data from the four causal mediation models produced similar results despite the\u003Cbr>􀀶 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | mediating role of molecular marker differing across scenarios, with heterogeneity effect sizes ranging from 1.47 to 1.60. Analyses of data from the two scenarios, in which molecular marker did not affect the risk of disease, also produced evidence of etiologic heterogeneity, with heterogeneity effect sizes of 1.53 and 2.66. The smallest heterogeneity effect size (1.33) was observed in the scenario in which molecular marker was a sufficient cause of disease.\u003Cbr>Conclusions: This methodologic research indicates that analyses of etiologic heterogeneity cannot distinguish between the modeled causal scenarios when a mediating or non-mediating molecular marker is used to subtype tumors.\u003Cbr>Impact: We discuss these results in the context of the literature on obesity and etiologic heterogeneity in breast tumors subtyped by sex hormone receptor status. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n\nIntroduction  \nA premise of molecular cancer epidemiology is that mechanistic hypotheses connecting exposures to cancers can be tested by incorporating data on molecular markers (biomarkers) into epidemiologic studies (1) . For example, a study exploring vinyl chloride carcinogenesis might include a marker of TP53 mutation to test whether the loss of TP53 function was implicated in vinyl chloride– induced angiosarcoma (2) . One analytic approach leveraging such biomarker data is the etiologic heterogeneity design described by Begg and colleagues (3–5). Etiologic heterogeneity analyses use data on tumor characteristics to subdivide cancer defined by a site (e.g., breast cancer) into subgroups (e.g., pathologic subtype or subtypes defined by hormone receptor status) that are thought to be more homogeneous in regards to a putative causa","cbCaiitngsaEVAao","https://ap.wps.com/l/cbCaiitngsaEVAao","pdf",1018413,"English","# Background\n# Methods\n# Results\n# Conclusions\n# Impact\n# Introduction","[{\"question\":\"What is the etiologic heterogeneity design and how are molecular markers used in it?\",\"answer\":\"Etiologic heterogeneity analyses use tumor characteristics and molecular markers to split a cancer defined by a site into subgroups. These subgroups are intended to be more homogeneous with respect to a suspected causal factor.\"},{\"question\":\"How does the study evaluate whether etiologic heterogeneity analyses can be interpreted under mediation?\",\"answer\":\"The study creates seven causal model scenarios from literature on postmenopausal breast cancer. It varies relationships among an exposure, a molecular marker (mediating or nonmediating), and disease, using numerical examples to assess how well analyses identify distinct etiologic pathways.\"},{\"question\":\"What do the results and conclusions indicate about distinguishing causal scenarios using molecular-marker subtyping?\",\"answer\":\"Heterogeneity analyses give similar results across multiple causal mediation models even when the mediating role of the molecular marker changes. The method cannot distinguish between the modeled causal scenarios when a mediating or nonmediating molecular marker is used to subtype tumors.\"}]","Can We Interpret Analyses of Etiologic Heterogeneity When Molecular Markers Are Used to Classify Tumors? | PDF",1790085060,15,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8a101fa799db5029342c569e0c66b5e6.webp",983,1315,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4f414ade954c84e2d25647a70ecf5ccb.webp",982,1314,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fd128ec9858ced8235f654c2f7daac02.webp",981,1312,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cef0f131dec20eaf61a8c56f12823927.webp",980,1311]